On November 10, Axsome Therapeutics rose 5.37% in Regular Trading, trading at $141.385 per share, with turnover of $29.0073 million.
The move aligns with continued market digestion of the company’s stronger-than-expected third-quarter results and the view that rising Auvelity revenue could support profitability in 2027.
Axsome Therapeutics reported third-quarter EPS of negative $0.25, better than consensus expectations of roughly negative $0.56 to negative $0.63, while revenue rose to $259.7 million from $171.0 million a year earlier and exceeded expectations near $249 million. Auvelity net product sales reached $207.6 million. Subsequent analyst commentary said the company could achieve earnings in 2027, supported by narrowing losses and expanding Auvelity sales, although the ramp in Alzheimer’s disease agitation remains a point to watch. Recent target-price cuts by some firms suggest valuation debate remains active even as ratings stayed constructive.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments